Clinical trials: Pancreatic Adenocarcinoma Resectable
Pancreas Adenocarcinoma
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor.
- Trial name
- NCT04998552
- Testing
- Cyberknife
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Capital Health System, Inc
Pancreatic Neoplasms, Pancreatic Cancer
Project Survival-Prospective Biomarker Discovery
This sample-collection study is open to participants in several categories: healthy volunteers (with or without a family history of pancreatic cancer) and individuals diagnosed with pancreatitis or any stage of pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Pancreatitis, Pancreatic Adenocarcinoma
- Trial name
- NCT02781012
- Where
- 6 sites in United States
- Volunteers
- 436 people, healthy volunteers welcome
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Cancer, PDAC
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- RASolute 304 (NCT07252232)
- Testing
- daraxonrasib
- Where
- 86 sites in United States, Canada and 8 more
- Volunteers
- 500 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021[7]-2030[6]), including a multidisciplinary training program…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Non-resectable, Chemotherapy Effect
- Trial name
- PREOPANC-4 (NCT05524090)
- Testing
- Implementation - International best-practice care
- Where
- Netherlands
- Volunteers
- 223 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas
The goal of this clinical research study is to learn if gemcitabine can enter pancreas cancer cells, to measure the amount of it that may enter the cells, and for biomarker testing.
- Trial name
- NCT01276613
- Testing
- Gemcitabine, Losartan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Adenocarcinoma
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer.
- Trial name
- NCT01206296
- Testing
- Intraperitoneal Gemcitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medstar Health Research Institute
Resectable Pancreatic Adenocarcinoma
Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis
The study aims at evaluating spatially resolved gene expression profiles of pancreatic and ampullary adenocarcinoma at favorable prognosis after surgical resection, in order to identify molecular features associated to a less…
- Trial name
- NCT05754788
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pancreatic Ductal Adenocarcinoma
Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
This clinical trial is looking at the effect of a new drug called GDC-0449 in patients with cancer of the pancreas. Laboratory studies have shown that this drug blocks a process in pancreatic cells thought to be involved in…
- Trial name
- HIPPoS (NCT01096732)
- Testing
- GDC-0449
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Lisa Bax
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma
- Trial name
- NCT03977233
- Testing
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Adenocarcinoma
Impact of Perioperative Nutritional Status and Management in the Context of Resectable Pancreatic Adenocarcinoma
Patients with pancreatic adenocarcinoma are frequently in a situation of malnutrition, in a context of functional alteration of the digestive tract, and hypercatabolism.
- Trial name
- PAAD (NCT06893536)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Carcinoma, Pancreatic Ductal
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
This is a prospective, single-center, single-arm, phase II clinical study. The primary purpose of the study was to evaluate the efficacy and safety of radiotherapy with sequential albumin-bound paclitaxel + Gemcitabine…
- Trial name
- NCT06573398
- Testing
- SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase Ib/II Open Label Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
The purpose of this study is to assess the safety, feasibility, and recommended dose of navlimetostat (BMS-986504) combined with mFOLFIRINOX before and after surgery in patients with localized pancreatic cancer with MTAP deletion.
- Trial name
- M-POP (NCT07905131)
- Testing
- Navlimetostat, mFOLFIRINOX Treatment Regimen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Daniel Nussbaum, M.D.
Pancreatic Cancer, Pancreatic Cancer Non-resectable
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06361030
- Testing
- surufatinib combined with gemcitabine plus nab-paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07645651
- Testing
- Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Pancreatic Adenocarcinoma Resectable, Non Metastatic
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.
This is an open master platform trial, which includes multi neo-adjuvant treatment trials, multi-center, national. This platform trial evaluates the major pathological response rate (mPR) after surgery.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1
- Trial name
- POWER (NCT07808567)
- Testing
- GnP, FOLFIRINOX
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Resectable Pancreatic Adenocarcinoma
Identify microRNAs in Cachexia in Pancreatic Carcinoma
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
- Trial name
- SCC-miRPanCa (NCT05275075)
- Testing
- Pancreatic cancer microRNA and messenger RNA expression.
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Oklahoma
Pancreatic Cancer
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.
- Trial name
- NCT03704662
- Testing
- Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Medical College of Wisconsin
Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
PULSAR in Systemic Therapy for Pancreatic Cancer
Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07269626
- Testing
- Personalized Ultrafractionated Adaptive Radiotherapy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samsung Medical Center
Pancreas Cancer, Pancreatic Cancer
A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer
This study is evaluating stereotactic radiosurgery (CyberKnife) plus chemotherapy for the treatment of potentially resectable adenocarcinoma of the pancreas
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma
- Trial name
- NCT02707315
- Testing
- Gemcitabine, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cooper Health System
Resectable Pancreatic Adenocarcinoma
Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer
A randomized, multidisciplinary study, Phase II-III clinical trial.The study is opened to the incorporation of other centers that would increase the power of the obtained results .
- Trial name
- NCT03251365
- Testing
- HIPEC-gemcitabine
- Where
- Spain
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hospital General de Ciudad Real